Auris Medical (EARS) Trading 7.7% Higher
Shares of Auris Medical Holding AG (NASDAQ:EARS) traded up 7.7% during mid-day trading on Friday . The company traded as high as $0.44 and last traded at $0.42. 1,071,609 shares were traded during trading, an increase of 122% from the average session volume of 482,252 shares. The stock had previously closed at $0.39.
Separately, Zacks Investment Research downgraded shares of Auris Medical from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th.
The company has a quick ratio of 1.86, a current ratio of 1.86 and a debt-to-equity ratio of -14.04.
About Auris Medical
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.
Receive News & Stock Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related stocks with our FREE daily email newsletter.